ES2811674R1 - Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria - Google Patents

Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria

Info

Publication number
ES2811674R1
ES2811674R1 ES202090057A ES202090057A ES2811674R1 ES 2811674 R1 ES2811674 R1 ES 2811674R1 ES 202090057 A ES202090057 A ES 202090057A ES 202090057 A ES202090057 A ES 202090057A ES 2811674 R1 ES2811674 R1 ES 2811674R1
Authority
ES
Spain
Prior art keywords
treatment
combination
ascorbic acid
quinone compounds
parasitic disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES202090057A
Other languages
English (en)
Other versions
ES2811674A2 (es
ES2811674B2 (es
Inventor
Sueli De Oliveira Silva Lautenschlager
Vania Cristina Desoti
Celso Vataru Nakamura
Valdecir Farias Ximenes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ic Medtech Corp
Original Assignee
Ic Medtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ic Medtech Corp filed Critical Ic Medtech Corp
Publication of ES2811674A2 publication Critical patent/ES2811674A2/es
Publication of ES2811674R1 publication Critical patent/ES2811674R1/es
Application granted granted Critical
Publication of ES2811674B2 publication Critical patent/ES2811674B2/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES202090057A 2018-06-06 2019-06-05 Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria Active ES2811674B2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862681500P 2018-06-06 2018-06-06
PCT/US2019/035501 WO2019236656A1 (en) 2018-06-06 2019-06-05 Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease

Publications (3)

Publication Number Publication Date
ES2811674A2 ES2811674A2 (es) 2021-03-12
ES2811674R1 true ES2811674R1 (es) 2021-09-20
ES2811674B2 ES2811674B2 (es) 2024-02-07

Family

ID=68769906

Family Applications (1)

Application Number Title Priority Date Filing Date
ES202090057A Active ES2811674B2 (es) 2018-06-06 2019-06-05 Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria

Country Status (11)

Country Link
US (2) US11872233B2 (es)
AR (1) AR115493A1 (es)
AU (1) AU2019282657B2 (es)
BR (1) BR112020024807A2 (es)
CA (1) CA3101331C (es)
CL (1) CL2020003143A1 (es)
CR (1) CR20200636A (es)
ES (1) ES2811674B2 (es)
MX (1) MX2020013076A (es)
PE (1) PE20212333A1 (es)
WO (1) WO2019236656A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110317A1 (es) 2016-12-06 2019-03-20 Ic Medtech Corp Compuestos de ácido ascórbico y quinona para tratar enfermedad de chagas
CA3101331C (en) * 2018-06-06 2023-12-19 IC-MedTech Corp. Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease
US20230130144A1 (en) * 2020-03-31 2023-04-27 Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. Pharmaceutical combination and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468414B1 (en) 2001-02-16 2002-10-22 Hydro-Quebec Method of purification of a redox mediator before electrolytic regeneration thereof
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
CA2689717C (en) 2006-06-16 2016-10-18 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2009035908A1 (en) 2007-09-11 2009-03-19 Wyeth Compositions and their use for the treatment of protozoal infections comprising metaflumi zone
WO2009063044A1 (en) 2007-11-16 2009-05-22 Pharmaq As Treatment of parasite diseases using vitamin k3
US9050265B2 (en) 2009-07-20 2015-06-09 Summa Health System Vitamin C and vitamin K, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant
EP2595615A1 (en) 2010-07-19 2013-05-29 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
WO2012018948A2 (en) 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
WO2014110305A1 (en) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamins c and k for treating polycystic diseases
EP3490543A4 (en) 2016-08-01 2020-04-01 IC-Medtech Corp. ASCORBIC ACID, CHINONE COMPOUND AND SODIUM GLUCOSE-COTRANSPORTER INHIBITOR FOR TREATING CANCER
CA3101331C (en) 2018-06-06 2023-12-19 IC-MedTech Corp. Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CASTRO JOSE A ET AL. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Human & Experimental Toxicology AUG 2006. , 31/07/2006, Vol. 25, Páginas 471-479 ISSN 0960-3271(print) ISSN 1477-0903(electronic), (DOI: doi:10.1191/0960327106het653oa) Ver resumen; páginas 473-475. *
ELINGOLD I ET AL. Mechanism of action of novel naphthofuranquinones on rat liver microsomal peroxidation. CHEMICO-BIOLOGICAL INTERACTIONS, 20091210 ELSEVIER SCIENCE IRLAND, IR. Wille Timo; Worek Franz; Thiermann Horst, 10/12/2009, Vol. 182, Páginas 213 - 219 ISSN 0009-2797, (DOI: doi:10.1016/j.cbi.2009.09.002) ver resumen; apartado 3. *
IBRAHIM M A ET AL. Antioxidant therapy against trypanosome infections: A review update. Current Topics in Medicinal Chemistry 20160801 Bentham Science Publishers are. , 01/08/2016, Vol. 16, Páginas 2233 - 2244 ISSN 1568-0266 (print) ISSN 1873-4294 (electronic), (DOI: doi:10.2174/1568026616666160413125622 pubmed:27072713) Ver resumen. *
INMACULADA RAMÏ¿¿REZ-MACÏ¿¿AS ET AL. Taiwaniaquinoid and abietane quinone derivatives with trypanocidal activity against T. cruzi and Leishmania spp. Parasitology International, vol. 61, n.3, 20120901. , 01/09/2012, Páginas 405 - 413 (DOI: doi:10.1016/j.parint.2012.02.001) Ver resumen; apartado 2. *
MOHAMED AMIN GHOBADIFAR ET AL. The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease. Revista da Sociedade Brasileira de Medicina Tropical, vol. 47, n. 5, 20141001. , 01/10/2014, Páginas 669 (DOI: doi:10.1590/0037-8682-0089-2014) Ver página 669. *
VÏ¿¿NIA CRISTINA DESOTI ET AL. The Combination of Vitamin K3 and Vitamin C Has Synergic Activity against Forms of Trypanosoma cruzi through a Redox Imbalance Process. PLOS ONE, 20151207. Langsley Gordon, 07/12/2015, Vol. 10, Páginas e0144033 (DOI: doi:10.1371/journal.pone.0144033) Ver resumen; resultados. *

Also Published As

Publication number Publication date
WO2019236656A1 (en) 2019-12-12
AU2019282657A1 (en) 2020-12-10
AU2019282657B2 (en) 2024-10-17
ES2811674A2 (es) 2021-03-12
MX2020013076A (es) 2021-03-02
CA3101331C (en) 2023-12-19
US20210361666A1 (en) 2021-11-25
AR115493A1 (es) 2021-01-27
BR112020024807A2 (pt) 2021-03-02
PE20212333A1 (es) 2021-12-14
US20240165084A1 (en) 2024-05-23
CR20200636A (es) 2021-06-10
CL2020003143A1 (es) 2021-06-11
CA3101331A1 (en) 2019-12-12
US11872233B2 (en) 2024-01-16
ES2811674B2 (es) 2024-02-07

Similar Documents

Publication Publication Date Title
CO2019008487A2 (es) Compuesto de quinazolina
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
ES2982308T3 (es) Péptido novedoso y composición farmacéutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmacéutico activo
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2014003455A1 (es) Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos.
ES2811674R1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
FR3032376B1 (fr) Ensemble de moulage et procede de fabrication d'un corps de seringue.
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
MA50358A (fr) Sémaglutide en thérapie médicale
CL2015002560A1 (es) Un método para tratar infecciones, enfermedades o desordenes de la unidad ungueal, con un dispositivo para implantar una composición en una ubicación determinada y un régimen de dosificación para tratar una enfermedad o trastorno de la unidad ungueal.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2811674

Country of ref document: ES

Kind code of ref document: A2

Effective date: 20210312

EC2A Search report published

Ref document number: 2811674

Country of ref document: ES

Kind code of ref document: R1

Effective date: 20210913

FG2A Definitive protection

Ref document number: 2811674

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20240207